(VIANEWS) – Viking Therapeutics (NASDAQ: VKTX) experienced an extraordinary 12.11% surge to EUR14.59 at 19:54 EST Monday evening – marking their third consecutive session of gains and falling into bear territory with the rest of NASDAQ. Although VKTX performed favorably against its competition, NASDAQ experienced overall bearish momentum with an 1.02% decrease to EUR14,159.47 which followed an upward trend. Viking Therapeutics closed at 13.00 on Monday; 49.42% below their 52-week high of EUR25.72
About Viking Therapeutics
Viking Therapeutics is a clinical-stage biopharmaceutical company focused on creating novel treatments for metabolic and endocrine conditions. VK2809, their lead drug candidate in Phase IIb trials for treating nonalcoholic steatohepatitis and NAFLD, is both tissue and receptor subtype selective agonist targeting thyroid hormone receptor beta. VK5211, an orally available non-steroidal selective androgen receptor modulator currently in Phase II development for non-elective hip fracture surgery patients, VK0612 for type 2 diabetes treatment, VK2735 (a dual agonist of glucagon-like peptide in Phase 1 SAD/MAD clinical trial), and VK0214 X-linked adrenoleukodystrophy treatment were all developed and are available from them. Established in 2012 and headquartered in California
Yearly Analysis
Viking Therapeutics stock currently trades at EUR14.59, significantly below its 52-week high of EUR25.72 and may have been oversold recently; however, it currently trades higher than its 52-week low of EUR3.54, suggesting it was undervalued at some point in time.
Noting the past does not guarantee future performance is key for investors and it is always advisable to conduct their own analysis and research prior to making investment decisions. Diversifying portfolios helps manage risk while limiting concentrated exposure in any particular stock or sector.
Technical Analysis
Viking Therapeutics stock price has fluctuated, currently being above its 50-day moving average of EUR10.89 while below its 200-day moving average of EUR15.16. Last reported volume for Viking Therapeutics was 2,031,408 which represents a decrease of 1.02% compared to average volume of 2,052,490.
Volatility-wise, the company has shown intraday variation averages for the last week, month, and quarter of 2.08%, 1.16%, and 3.27%, respectively. Furthermore, their highest average volatility range was between 3.27% (last week), 3.81% (month), and 3.27% (quarter).
The stochastic oscillator, an indicator for overbought and oversold conditions, classifies Viking Therapeutics stock as oversold (=20) according to its current value.
Quarter Analysis
Based on available information, the company’s projected quarterly growth estimate stands at 3.8%; this indicates moderate short-term expansion. However, its projection for next quarter shows a drop-off by 8 percentage points and suggests potential difficulties ahead.
Notably, estimates may differ depending on various factors like market conditions and economic trends as well as company performance. Thus, investors must carefully consider this information within the context of a company’s overall financial health and prospects before making investment decisions.
Equity Analysis
Viking Therapeutics currently has an trailing twelve months EPS of EUR-0.92, suggesting the company is incurring losses. This information could be alarming to potential investors as it indicates the lack of profits needed to support operations or reward shareholders with dividends.
Additionally, the company’s return on equity (ROE) for the twelve trailing months stands at negative -31.12% indicating it does not generate sufficient profit relative to shareholder equity. A negative ROE may signal ineffective asset utilization by management that may cause concern among potential investors.
Overall, these financial metrics suggest that Viking Therapeutics may not be performing optimally when it comes to profitability. Investors may wish to take these factors into consideration as well as other relevant information regarding growth prospects and competitive position before making their investment decision.
More news about Viking Therapeutics (VKTX).
